Member Info for B2HS2L

Also:
...available within the next two weeks. The purchase of further raw materials and a further scale up
of manufacturing capacity is possible under this outsourcing agreement.

https://www.channel4.com/news/rapid-covid-19-self-testing-kit-set-for-uk-release

Well surely worst case it's got to be 50% accurate.

You could make the same decision with 10 p coin

Updated entry on FIND (https://www.finddx.org/covid-19/)

Roche Molecular Diagnostics, cobas® SARS-CoV-2 (for use on the cobas® 6800/8800 Systems; US FDA-EUA)

Nothing listed about CE-IVD

Well that's most of Friday gone in Washington..

"It is for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples"
I could go for quantative (but crap) detection.

https://www.genomeweb.com/regulatory-news-fda-approvals/fda-issues-emergency-use-authorization-roche-sars-cov-2-test#.XmuxREdzxQI

FDA Issues Emergency Use Authorization for Roche SARS-CoV-2 Test
Mar 13, 2020 | staff reporter
NEW YORK – Roche said on Friday that the US Food and Drug Administration has issued Emergency Use Authorization for the Cobas SARS-CoV-2 Test.

The test, which is also CE-IVD marked, is for patients who show signs and symptoms of the disease COVID-19, caused by the SARS-C0V-2 coronavirus. It is for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients who meet the clinical and epidemiological criteria for testing, and can be used with Roche's fully automated Cobas 6800 and Cobas 8800 systems.

The Cobas SARS-CoV-2 Test is a real-time, reverse transcriptase PCR test. The single-well, dual target assay includes specific detection of SARS-CoV-2 and pan-sarbecovirus detection for the sarbecovirus subgenus family that includes the novel coronavirus that has infected nearly 133,000 people worldwide. Almost 5,000 people have died from COVID-19.

Roche noted that negative results with the Cobas SARS-CoV-2 Test does not preclude infection and such results must be combined with clinical observations, patient history, and epidemiological information.

"Over the last weeks, our emergency response teams have been working hard to bring this test to the patients," Roche Diagnostics CEO Thomas Schinecker said in a statement. "CE-mark certification and the FDA’s granting of EUA supports our commitment to give more patients access to reliable diagnostics which are crucial to combat this serious disease."

Roche said that upon the authorization it will have millions of tests each month for use on the two Cobas systems and is "going to the limits of our production capacity."

Aside from Roche, the US Centers for Disease Control and Prevention, and New York state have received FDA EUA for SARS-CoV-2 tests. Hackensack Meridian Health CDI was granted preliminary EUA for its coronavirus test

+++++++

PRELIMINARY EUA? *ollocks!

"Roche noted that negative results with the Cobas SARS-CoV-2 Test does not preclude infection and such results must be combined with clinical observations, patient history, and epidemiological information." - Still room for NCYT then.
How can a health authority be happy with these results?
Because it churns out so many in unit time..

People want to see the rise due to EUA, then sell into that rise I believe.
This news is as likely to arrive any time today, Saturday or Sunday, even Monday - every day is a working day now.

Acquiring the CE label first, meant Primerdesign were the first company for health authorities to start discussions with for the 28 European nations.
It would be good to hear how successful we have been in EU nations other than Frnce and Poland :) and Germany :(
MENA nations for whom the CE label is held in high regard are coming along nicely.

Trump is trying hard to make sure voters see it is himself who is improving the 'not enough testing facilities' scenario.
But it will be Trump who loses votes most if this situation blows up in his face.
Standby for EUA news.
Oh, - and wouldn't want to be out of this over the weekend.
Because this is going to be a working weekend on this subject.

Can you confirm it was on Twitter please, - I have been looking on LinkedIn but did'nt find it.

BLOWNITALREADY Re your 12:32 post.

"Two diagnostic tests that may detect severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in approximately one hour will receive advanced development support from the U.S.

The Biomedical Advanced Research and Development Authority (BARDA) within ASPR will provide approximately $679,000 to DiaSorin Molecular, LLC of Cypress, California, to rapidly develop the Simplexa COVID-19 Direct Assay, and approximately $598,000 to QIAGEN LLC of Germantown, Maryland, to accelerate development of the QIAstat-Dx RPS2 test for COVID-19. The companies will provide the remaining funds for developing their respective diagnostic tests."


From FIND:
https://www.finddx.org/covid-19/

QIAGEN GmbH, QIAstat-Dx Respiratory Panel 2019-nCoV (lab-based or near-POC; RUO)
Note: not the QIAstat-Dx RPS2 mentioned the above quote.

Simplexa COVID-19 Direct Assay
Note: Not found on FIND.

++++

Both of these instruments require development, and FIND does not list one of them.
This is a gamble that development will produce tangible results in the required timescale.

From y'day RNS:
"However, it is clear that the demand for, and interest in, the Company's tests remains very high and the Directors' key focus is on ensuring Primerdesign can service the demand from as many customers as possible."

This fly's directly in the face of the Polish assertion that they bought all the tests available from Primerdesign.
I believe it would be bad business for Primerdesign to sell all tests to one customer, because when other customers found nil stock available, they would loose faith in all future availability.
IMO the Polish bought the amount the company was willing to sell them.

68,000,000 shares in issue * 3% = 2,040,000 = largest amount of shares a single shareholder can own without notifying.

Source: Morning Star
https://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=5&vw=own&SecurityToken=0P0001BXXQ%5D3%5D0%5DE0WWE%24%24ALL&Id=0P0001BXXQ&ClientFund=0&CurrencyId=BAS

NYCT Major Shareholders:
Name, Amount, Holding%
Vatel Capital 4,784,384 12.28
Legal and General 2,525,909 6.49
Alto Invest 1,861,447 4.78
Nyenburgh Investment Partners 1,515,151 3.89

NYCT Shareholders:
Name, Amount, Holding%
Mr. Jean-Pierre Jacques Crinelli 91,090 0.242
Graham D. Mullis 52,138 0.138
Dr. Andrew John William Heath 16,839 0.045

Vatel Capital.

source: https://www.vatelcapital.com/en-quelques-mots/:

WHO ARE WE?

Founded in 2008, Vatel Capital is an independent and entrepreneurial management company accredited by the AMF and registered with the RCS in Paris under 507 646 883. We specialise in supporting listed and unlisted French growth SMEs. Our strength lies in a team of managers who have worked together for more than fifteen years.

Vatel Capital was awarded the Morningstar Springboards in 2011 for the most dynamic portfolio management company in the "unlisted" category. In 2015, the Vatel Small Caps Flexible CPF was awarded the Lipper Fund Award. In January 2016 and 2017, Vatel Capital was rated 4 stars by Fortune Management for its quality of service. In March 2017, Vatel Capital was voted the 3rd preferred company for IFAs in the "Capital Investment" category of the journal Investments Conseils. In 2018, the VAtel Small Caps Flexible FCP wins the Lipper Fund Award for the second time.

Our values

Independence

Vatel Capital is wholly owned by its employees. We work continuously in the interests of our policyholders and the SMEs we support. We take scrupulous care to outlaw any conflict of interest. See our policy in this regard: conflict of interest management policy and voting policy.

Entrepreneurship

We are entrepreneurs ourselves and know the joys but also the doubts that business creation engenders. Our approach is pragmatic and we are generally present on the advice of our participations to support entrepreneurs.

Respect

At Vatel Capital, we know from experience that creating and managing a business is a perilous exercise. We work with executives as advisors and accelerators, but do not interfere in corporate management.

Performance

We invest our own money in the funds we manage. Our goal is to achieve profitability above the stock market over an average time horizon of 5 years, through funds with a locking period of between 6 and 10 years.

Good man - you wouldn't want your balls trampled on would you.

If too many want Primerdesign kits and equipment, then there will have to be some licensing deals along soon.

"In the past two weeks, the number of countries the Company is selling its COVID-19 test into
has doubled to over 50, which is expected to increase further as the virus continues to spread."

So are new customers operating with qPCR equipment that is compatible with the Test Kit's? - Not very likely
If they are new customers they won't have Primerdesign instruments.
Many new customers will need the (q16 and q32) equipment as well as test kits. Profit should be around £3K an instrument, and I expect many instrument orders for many locations.

Chimers:
NCYT, smashing sales targets, NO debt, CASH in bank. whats not to like
P.S. And not a one trick pony!

Don't forget Payment with order, - no cash flow issues.

Trump is looking to improve his chances of getting votes.
If he can do this by making others look like they aren't performing well / have made stupid decisions he will.
Likewise if he can pull a Rabbit out the hat so that he himself is seen as improving the present US testing scenario he will.
I'm standing by for EUA being granted courtesy of personal intervention from Trump, because he needs to be seen as the cure for the lack of testing facilities problem.

Todays RNS:
1 RNS mentions tests only, no mention of how many instrument (q16 and q32) orders there are. - (Unsure where these are manufactured).

2 "In the past two weeks, the number of countries the Company is selling its COVID-19 test into
has doubled to over 50, which is expected to increase further as the virus continues to spread."

So are new customers operating with qPCR equipment that is compatible with the Test Kit's?
If they are new customers they won't have Primerdesign instruments.
So many new customers will need the (q16 and q32) equipment as well as test kits.
Profit should be around £3K an instrument, and I expect many instrument orders for many instrument locations.

3 As Trump is minimising inter-continental flights - Europe first others next probably.
Will he re-instate flights only with passengers testing negative first?
- a possibility, why would he care how inconvenient this might be.
It would help greatly if the equipment tested the Asymptomatic as well as the symptomatic with equal accuracy. - Which other manufacturer can provide that?

4 "The purchase of further raw materials and a further scale up of manufacturing capacity is possible under this outsourcing agreement."
For continuity of supply I would expect any further capacity to be arranged elsewhere.

I see a gap up for the sp tomorrow.
Time for news to circulate tonight about the French Govnts use of NCYT and Primerdesign.
Possibly £1.25 at 08:00 tomorrow, with more to come from then on.